Investing News

Cytokinetics Stock Skyrockets on Positive Results from Study of Its Heart Drug

Cytokinetics Inc. reported positive results Wednesday from a key Phase 3 study of its experimental drug to treat heart disease.

Articles You May Like

All In: Daniel Loeb Put 37% of Portfolio in These 3 Stocks. Masterstroke or Misstep?
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Robotics Stocks
The Unshakeable Seven: Bet On These Consumer Defensive Stocks to Navigate Market Mayhem
3 Retail Stocks Most at Risk of the New Cautious Consumer Trend
Why is Accumulated Depreciation a Credit Balance?